According to Reuters reported on the 20th, a small preliminary laboratory study released recently showed that after receiving two doses of Russian "satellite V" vaccine, the level of Omiljung neutralizing antibodies in the vaccinator's body was higher than that of two doses of Pfizer.
The antibody level is more than 2 times
The study was funded by the Russian Direct Investment Fund and was carried out by scientists from the National Institute of Infectious Diseases of Lazaro Spalanzani in Italy, the Gamaleya State Research Center for Epidemiology and Microbiology in Russia and the First State Medical University of Shechenov in Moscow. The study was published on the 19th on the preprint platform MedRxiv.
The study compared the effectiveness of the Satellite V and Pfizer vaccines against The Omex rong, using serum samples from the two vaccines, including 51 two-dose Satellite V vaccinators and 17 2-dose Pfizer vaccinators.
The researchers note that the "satellite V" vaccine neutralizes the Omiljung strain, and that it relies on high levels of antibodies to produce a stronger immune response. The data showed that neutralizing antibodies against Omikron were detected in the serum samples of 74.2% of "satellite V" vaccinators, compared with 56.9% for the Pfizer vaccine.
Overall, Satellite V's neutralizing antibody levels to Theomexon were 2.1 times higher than those of the Pfizer vaccine, and three months after vaccination, the antibody levels were 2.6 times that of Pfizer.
The study also notes that "the need for a third booster vaccine is evident at this time".
A previous study by the Gamaleya Research Center showed that another satellite Light booster injection compared to only two doses of "satellite V" can significantly enhance the antibody response to Omikeron.
The "Satellite V" vaccine was officially launched in August 2020 and is the world's first registered COVID-19 vaccine. The vaccine is produced jointly by the Gamaleya Research Center in Russia and the company Binnopharm.
According to the Russian Satellite News Agency, "Satellite V" has now been approved in more than 70 countries around the world, covering a total population of 4 billion.
At present, the number of officially reported cases in Russia exceeds 1,600, and the number of new COVID-19 cases in the country in a single day has recently exceeded 30,000.
Adenovirus vector vaccine
This study has once again aroused the attention of all walks of life about adenovirus vector vaccines.
At present, "Satellite V" and Johnson & Johnson's Janssen vaccine in the United States, as well as the vaccine jointly developed by AstraZeneca and Oxford in the United Kingdom, are all adenovirus vector vaccines. Pfizer and Modena, on the other hand, use mRNA (Messenger Ribonucleic Acid) technology. These two types of vaccines induce different immune responses.
Previously, scientists in the United States and Argentina conducted comparative studies of several new crown vaccines and found that vaccines with human adenovirus as the carrier have better protection time than mRNA vaccines.
A study published in the New England Journal of Medicine last October pointed out that mRNA vaccines have a peak antibody response to the new crown virus, but gradually lose most of their efficacy within 6 months, while adenovirus vector vaccines can still provide stable protection for 8 months after vaccination.
Another peculiarity of "Satellite V" is that it uses a combined immunization model, that is, two doses of vaccine based on different adenoviral vectors need to be injected before and after, the first dose is based on adenoviral vector Ad-26, and the second dose is based on adenoviral vector Ad-5 after 21 days. In contrast, the Janssen vaccine uses only the adenoviral vector Ad-26.
Scholars believe that "Satellite V" proposes a new method of immunity against the new crown virus - "adenovirus heterologous recombination method", which is essentially a mixed vaccine, so it is also called "cocktail therapy".
A study of the safety and efficacy of Satellite V published in The Lancet in February last year showed that heterologous immunization provided a powerful cellular immune response with a 91.6% effectiveness against the new coronavirus.
(Edit email: [email protected])
Column Editor-in-Chief: Yang Liqun Text Editor: Yang Liqun Title Image Source: Visual China Image Editor: Su Wei
Source: Author: Yang Ying
![The materials required for Uganda's return to China are as follows; 1. Materials required for passengers to China to apply for a health code (1) All passengers going to China are required to submit the following materials 1, before boarding by a testing agency recognized by the Embassy 4[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)